The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Programmed death-1 pathway in cancer and autoimmunity
Open accessAbstract
Programmed death-1 (PD-1) is a co-receptor that is expressed predominantly by T cells. The binding of PD-1 to its ligands, PD-L1 or PD-L2, is vital for the physiologic regulation of the immune system. A major functional role of the PD-1 signaling pathway is the inhibition of self-reactive T cells, which serve to protect against autoimmune diseases. Elimination of the PD-1 pathway can therefore result in the breakdown of immune tolerance that can ultimately lead to the development of pathogenic autoimmunity. Conversely, tumor cells can at times co-opt the PD-1 pathway to escape from immunosurveillance mechanisms. Therefore, blockade of the PD-1 pathway has become an attractive target in cancer therapy. Recent clinical trials have shown that anti-PD-1 agents have profound effects on solid tumor regression. Current approaches include six agents that are either PD-1 and PD-L1 targeted neutralizing antibodies or fusion proteins. More than forty clinical trials are underway to better define the role of PD-1 blockade in variety of tumor types. In this review we will highlight the basic biology of the PD-1 system and discuss its potential roles in both autoimmunity and cancer. We propose that future research on PD-1 may lead to the translation of fundamental regulatory pathways into the development of practical new approaches for the treatment of autoimmune diseases and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Tissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
Fife, B. T., Pauken, K. E., Eagar, T. N., Obu, T., Wu, J., Tang, Q., Azuma, M., Krummel, M. F., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1790 · Cited by 759
The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood
Sage, P. T., Francisco, L. M., Carman, C. V., & Sharpe, A. H. (2013) · Nature Immunology · doi:10.1038/ni.2496 · Cited by 467
PD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365
B7 family checkpoint regulators in immune regulation and disease
Ceeraz, S., Nowak, E. C., & Noelle, R. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.003 · Cited by 307
Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
Gianchecchi, E., Delfino, D. V., & Fierabracci, A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.003 · Cited by 270
Ha, S.-J., Mueller, S. N., Wherry, E. J., Barber, D. L., Aubert, R. D., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071949 · Cited by 211
Raptopoulou, A. P., Bertsias, G., Makrygiannakis, D., Verginis, P., Kritikos, I., Tzardi, M., Klareskog, L., Catrina, A. I., Sidiropoulos, P., & Boumpas, D. T. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27500 · Cited by 191
Fuller, M. J., Callendret, B., Zhu, B., Freeman, G. J., Hasselschwert, D. L., Satterfield, W., Sharpe, A. H., Dustin, L. B., Rice, C. M., Grakoui, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312772110 · Cited by 173
Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo
Becker-Gotot, J., Gottschalk, C., Leopold, S., Knolle, P. A., Yagita∥, H., Kurts, C., & Ludwig‐Portugall, I. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201131109 · Cited by 168
PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A
Patsoukis, N., Sari, D., & Boussiotis, V. A. (2012) · Cell Cycle · doi:10.4161/cc.22135 · Cited by 143
Yang, W., Chen, P. W., Li, H., ALIZADEH, H. M., & Niederkorn, J. Y. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1606 · Cited by 137
Finger, L. R., Pu, J. J., Wasserman, R., Vibhakar, R., Louie, E., Hardy, R. R., Burrows, P. D., & Billips, L. G. (1997) · Gene · doi:10.1016/s0378-1119(97)00260-6 · Cited by 113
Robert, C., Soria, J., & Eggermont, A. M. M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.001 · Cited by 95
Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T cells in Rheumatoid Arthritis
Li, S., Liao, W., Chen, M., Shan, S., Song, Y., Zhang, S., Song, H., & Yuan, Z. (2013) · Inflammation · doi:10.1007/s10753-013-9718-8 · Cited by 82
Insights into the Role of Follicular Helper T Cells in Autoimmunity
Park, H.-J., Kim, D.-H., Lim, S., Kim, W., Youn, J., Choi, Y.-S., & Choi, J. (2014) · Immune Network · doi:10.4110/in.2014.14.1.21 · Cited by 80
Kobayashi, M., Kawano, S., Hatachi, S., Kurimoto, C., Okazaki, T., Iwai, Y., Honjo, T., Tanaka, Y., Minato, N., Komori, T., et al. (2005) · PubMed · Cited by 77
Pittet, C. L., Newcombe, J., Prat, A., & Arbour, N. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-155 · Cited by 73
Wong, M., Cava, A. L., & Hahn, B. H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202382 · Cited by 73
Kristjansdottir, H., Steinsson, K., Gunnarsson, I., Gröndal, G., Erlendsson, K., & Alarcón-Riquelme, M. E. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27417 · Cited by 70
Chen, Y., Wu, S., Guo, G., Fei, L., Guo, S. J., Yang, C., Fu, X., & Wu, Y. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001347 · Cited by 47
Nicholas, K. J., Zern, E. K., Barnett, L. D., Smith, R. M., Lorey, S. L., Copeland, C. A., Sadagopal, S., & Kalams, S. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084185 · Cited by 37
Tahoori, M. T., Pourfathollah, A. A., Akhlaghi, M., Daneshmandi, S., Nicknam, M. H., & Soleimanifar, N. (2011) · PubMed · Cited by 33
Blocking PD-1 in cancer immunotherapy
Dotti, G. (2009) · Blood · doi:10.1182/blood-2009-05-223412 · Cited by 33
Cited by
Role of the Tumor Microenvironment in Breast Cancer
Soysal, S. D., Tzankov, A., & Muenst, S. E. (2015) · Pathobiology · doi:10.1159/000430499 · Cited by 510
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
PD-1 and its ligands are important immune checkpoints in cancer
Dong, Y., Sun, Q., & Zhang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 334
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Five Layers of Receptor Signaling in γδ T-Cell Differentiation and Activation
Ribeiro, S. T., Ribot, J. C., & Silva-Santos, B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00015 · Cited by 116
Metadata
- Authors
- Pedoeem, A., Azoulay-Alfaguter, I., Strazza, M., Silverman, G. J., & Mor, A.
- Venue
- Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 153
- Issue
- 1
- Pages
- 145-152
- ISSN
- 1521-6616 (ISSN-L)
- OpenAlex
- W2085768658
- Cited by
- 268
- References
- 30
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.